Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Issue 8 (September 2015)

• Record Type: Journal Article
• Authors: Hecht, J. Randolph; Douillard, Jean-Yves; Schwartzberg, Lee; Grothey, Axel; Kopetz, Scott; Rong, Alan; Oliner, Kelly S.; Sidhu, Roger
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 8(2015)
• Page Start: 653
• Page End: 659
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.05.008
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title id="st005">Highlights</title> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0005">Panitumumab and cetuximab are effective therapies for metastatic colorectal cancer.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0010"> <italic>KRAS</italic> exon 2 mutation status has been used to guide anti-EGFR therapy.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0015">Many patients have tumors with other <italic>RAS</italic> mutations (<italic>KRAS</italic> exon 3/4; <italic>NRAS</italic> exons 2/3/4).</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0020">Recent evidence indicates that these mutations can also guide anti-EGFR therapy.</p> </list-item> </list> </p> </sec> </abstract>